Breaking News

Cedarburg Hauser Site Granted DEA Registration

February 27, 2013

Denver facility can manufacture schedule II-V controlled substances

Cedarburg Hauser’s Denver, CO facility has been granted registration as a manufacturer of schedule II-V controlled substances by the U.S Drug Enforcement Agency (DEA). The new DEA registration status allows the company to manufacture controlled substances and provides additional capacity when added to its existing controlled substance manufacturing capabilities at its Grafton, WI facility.
 
"The GMP manufacturing and analytical method development expertise of Cedarburg Hauser's Denver facility may now be extended to DEA scheduled compounds," said vice president and general manager, Joe Guiles. "This further emphasizes these competencies, and represents an opportunity to expand our customer base and serve the needs of our existing customers."
 
"The development and manufacturing of controlled substances requires stringent controls and security measures," said Dan Childers, vice president of Quality Assurance and Regulatory Compliance. "DEA registration further illustrates the strength of the manufacturing, handling and storage controls in place at Cedarburg Hauser's Denver facility."

blog comments powered by Disqus
  • CMC Biologics: Growing Through Innovation

    Tim Wright, Editor||January 28, 2016
    The new chief exec talks about industry trends and growth plans.

  • Cold-Chain Logistics & The Central Lab

    Kristin Brooks, Associate Editor||January 28, 2016
    Eric Hayashi of LabConnect discusses safety measures to ensure sample integrity

  • A Look at DCAT Week ‘16

    Tim Wright, Editor||January 28, 2016
    On the pulse of the pharmaceutical manufacturing value chain, DCAT Week ‘16 will deliver top-flight education programs and networking events.